SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00109278

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured From the 2003 Measles Stock Seed With Recombinant Human Albumin (rHA) Versus Currently Licensed V205C Manufactured From the 1967 Measles Stock Seed With Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age

The purpose of this study is to test the safety of a measles, mumps, and rubella study vaccine made from a new measles stock seed (a component of the vaccine made in 2003) with rHA (recombinant human albumin).

NCT00109278 Measles
MeSH: Measles

2 Interventions

Name: V205C, measles, mumps, and rubella virus vaccine live

Type: Biological

Name: Comparator: Measles, Mumps, and Rubella Virus Vaccine Live

Type: Biological


Primary Outcomes

Measure: Antibody response rate to measles at 6 weeks postvaccination

Secondary Outcomes

Measure: Geometric mean titers to measles by ELISA at 6 weeks postvaccination

Purpose: Prevention

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 V205C

A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured From the 2003 Measles Stock Seed With Recombinant Human Albumin (rHA) Versus Currently Licensed V205C Manufactured From the 1967 Measles Stock Seed With Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age. --- V205C ---

A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured From the 2003 Measles Stock Seed With Recombinant Human Albumin (rHA) Versus Currently Licensed V205C Manufactured From the 1967 Measles Stock Seed With Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age. --- V205C --- --- V205C ---

A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED) The purpose of this study is to test the safety of a measles, mumps, and rubella study vaccine made from a new measles stock seed (a component of the vaccine made in 2003) with rHA (recombinant human albumin). --- V205C ---



HPO Nodes